Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.63 |
| ▸ | DRD1 | P21728 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13686427 | 0.90 | KCNH2 (0.69) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL4669298 | 0.84 | OPRM1 (0.58) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL7977689 | 0.83 | OPRM1 (0.78) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL8175607 | 0.83 | OPRM1 (0.78) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL3919536 | 0.83 | OPRM1 (0.78) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL8186671 | 0.83 | OPRM1 (0.78) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL17282159 | 0.83 | CYP2D6 (0.74) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL3395443 | 0.82 | HRH3 (0.61) | KMT2AMEN1LMNANPSR1HRH3 | |
| SCHEMBL13900831 | 0.81 | ACHE (0.54) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 | |
| SCHEMBL2476728 | 0.81 | OPRM1 (0.58) | OPRM1CYP2D6CHRM2ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696707-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | OPRM1 3322/4885CYP2D6 2158/4885CHRM2 4812/4885 |
| US-20070219254-A1 | Therapeutic Compounds: Pyridine N-Oxide Scaffold | OPRM1, OPRL1, OPRD1 | OPRM1 1/4885CYP2D6 258/4885CHRM2 37/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | OPRM1 9/4885CYP2D6 178/4885CHRM2 72/4885 |
| US-10696707-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | OPRM1 3322/4885CYP2D6 2158/4885CHRM2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.